secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001193125-25-311202
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Terns reports 64% MMR rate in Phase 1 CARDINAL trial of TERN-701 in CML; selects 320/500 mg RP2D
--------------------------------------------------------------------------------

- Overall MMR rate of 64% (18/28) achieved by 24 weeks; cumulative MMR rate 74% (28/38).
- At doses >=320 mg QD (RP2D), MMR achievement 75% (18/24) by 24 weeks; DMR rate 36% (10/28).
- Safety: 87% patients on treatment; no DLTs; low Grade 3+ cytopenia (<10%); common TEAEs diarrhea, headache, nausea.
- Enrollment surpassed 85 patients; company plans pivotal Phase 3 trials in 2L+ and 1L CML in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000119312525311202/0001193125-25-311202-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000119312525311202/d19462d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-311202

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer